…
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits. Its products include Slimbiome, which offers a scientifically supported, non-pharmaceutical approach to reduce hunger and cravings; CholBiome, a food supplement for reducing cholesterol and blood pressure and supporting vascular health; and Sweetbiotix which are dietary fibres used as an alternative to sugar and existing sweeteners. The company also provides WellBiome a novel in vitro model of the human gut; OptiBiotics, a portfolio of prebiotics developed to target and enhance the growth of specific probiotics; and SlimBiome X3, a supplement that helps users cut calories without hunger and cravings. The company was formerly known as Ducat Ventures PLC and changed its name to OptiBiotix Health Plc in August 2014. OptiBiotix Health Plc was incorporated in 2006 and is headquartered in York, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -1.87M | -2.04M | 2.44M | 6.18M | 5.71M |
| Minority interest | - | - | 0.00M | 0.00M | 0.04M |
| Net income | -1.80M | -2.04M | 2.59M | 6.26M | 5.80M |
| Selling general administrative | 1.65M | 1.70M | 0.83M | 0.93M | 0.74M |
| Selling and marketing expenses | 0.65M | 0.12M | 0.16M | 0.11M | 0.17M |
| Gross profit | 0.33M | 0.32M | 0.24M | 1.12M | 0.88M |
| Reconciled depreciation | 0.21M | 0.20M | 0.22M | 0.29M | 0.25M |
| Ebit | -2.27M | -2.04M | -2.49M | -1.37M | -1.11M |
| Ebitda | -2.06M | -1.84M | -2.35M | -1.08M | -1.17M |
| Depreciation and amortization | 0.21M | 0.20M | 0.14M | 0.29M | -0.06M |
| Operating income | -2.27M | -1.70M | -2.49M | -1.37M | -1.11M |
| Other operating expenses | 3.14M | 2.34M | 2.94M | 3.58M | 2.63M |
| Interest expense | - | 0.00M | 5.01M | 0.05M | 0.04M |
| Tax provision | -0.06M | -0.00M | -0.15M | -0.08M | -0.09M |
| Interest income | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | 0.00M | 0.00M | 0.00M | -0.05M | -0.04M |
| Income tax expense | -0.06M | -0.00M | -0.15M | -0.08M | -0.09M |
| Total revenue | 0.87M | 0.64M | 0.46M | 2.21M | 1.52M |
| Total operating expenses | 2.60M | 2.02M | 2.73M | 2.49M | 1.99M |
| Cost of revenue | 0.54M | 0.32M | 0.21M | 1.09M | 0.64M |
| Total other income expense net | 0.40M | -0.35M | 4.93M | 7.54M | 6.82M |
| Net income from continuing ops | -1.80M | -2.04M | 2.59M | 6.26M | 5.80M |
| Net income applicable to common shares | - | - | 2.59M | 6.26M | 5.80M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 9.04M | 9.40M | 11.55M | 20.14M | 13.70M |
| Intangible assets | 1.12M | 1.33M | 1.54M | 2.64M | 2.74M |
| Other current assets | 0.02M | 0.10M | - | 1.74M | 0.96M |
| Total liab | 0.65M | 0.53M | 0.64M | 1.97M | 1.85M |
| Total stockholder equity | 8.40M | 8.87M | 10.90M | 18.14M | 11.82M |
| Other current liab | 0.10M | 0.12M | 0.09M | 0.18M | 0.16M |
| Common stock | 1.96M | 1.82M | 1.82M | 1.76M | 1.76M |
| Capital stock | 1.96M | 1.82M | 1.82M | 1.76M | 1.76M |
| Retained earnings | 0.58M | 1.82M | 3.68M | 11.32M | 5.06M |
| Other liab | - | - | 0.36M | 0.55M | 0.56M |
| Cash | 0.74M | 0.64M | 1.05M | 2.01M | 0.86M |
| Total current liabilities | 0.37M | 0.18M | 0.28M | 0.60M | 0.52M |
| Net debt | -0.74M | -0.64M | -1.05M | -1.19M | -0.09M |
| Short long term debt total | - | - | - | 0.82M | 0.77M |
| Other stockholder equity | 4.11M | 2.96M | 5.40M | 5.06M | 5.00M |
| Total current assets | 1.42M | 1.38M | 1.86M | 3.85M | 2.01M |
| Net tangible assets | - | - | 9.37M | 15.50M | 9.08M |
| Net receivables | 0.43M | 0.46M | 0.38M | 1.69M | 0.93M |
| Long term debt | - | - | 0.00M | 0.82M | 0.77M |
| Inventory | 0.23M | 0.19M | 0.18M | 0.10M | 0.18M |
| Accounts payable | 0.27M | 0.06M | 0.19M | 0.42M | 0.36M |
| Accumulated other comprehensive income | 1.75M | 2.27M | - | - | -0.01M |
| Common stock total equity | - | - | - | - | 1.76M |
| Non currrent assets other | - | - | 8.15M | 13.65M | 8.96M |
| Non current assets total | 7.62M | 8.02M | 9.69M | 16.29M | 11.70M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | 0.59M | 1.11M | -0.33M | -0.19M | -0.35M |
| Change to liabilities | - | - | -0.02M | 0.08M | -0.04M |
| Total cashflows from investing activities | 0.59M | 1.11M | -0.33M | -0.19M | -0.35M |
| Total cash from financing activities | 1.28M | - | 0.48M | 2.90M | 1.69M |
| Net income | -2.27M | -2.04M | -2.49M | -1.37M | -1.11M |
| Change in cash | 0.10M | -0.42M | -0.95M | 1.14M | 0.41M |
| Begin period cash flow | 0.64M | 1.05M | 2.01M | 0.86M | 0.46M |
| End period cash flow | 0.74M | 0.64M | 1.05M | 2.01M | 0.86M |
| Total cash from operating activities | -1.77M | -1.53M | -1.11M | -1.56M | -0.93M |
| Issuance of capital stock | 1.28M | 0.00M | 0.48M | 0.00M | 0.94M |
| Depreciation | 0.21M | 0.20M | 0.22M | 0.29M | 0.25M |
| Other cashflows from investing activities | - | 1.11M | - | - | - |
| Change to inventory | -0.04M | -0.01M | -0.08M | 0.08M | -0.12M |
| Change to account receivables | 0.03M | 0.06M | 1.12M | -0.91M | -0.04M |
| Other cashflows from financing activities | - | 1.11M | -0.33M | 2.90M | 0.75M |
| Change to netincome | - | - | -4.94M | -7.37M | -6.78M |
| Capital expenditures | 0.00M | 0.00M | 0.17M | 0.19M | 0.35M |
| Change in working capital | 0.17M | -0.05M | 1.02M | -0.74M | -0.20M |
| Stock based compensation | 0.05M | 0.01M | 0.01M | 0.06M | 0.13M |
| Other non cash items | 0.07M | 0.35M | 0.12M | 0.19M | 0.01M |
| Free cash flow | -1.77M | -1.53M | -1.28M | -1.76M | -1.28M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(GBX) |
Price
(GBX) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| OPTI OptiBiotix Health Plc |
- -% |
5.65 | - | - | 4.71 | 0.64 | 3.54 | -1.39 |
| GNS Genus PLC |
18.00 0.78% |
2340.00 | 36.08 | 26.18 | 2.53 | 3.46 | 2.92 | 15.38 |
| ONT Oxford Nanopore Technologies Ltd |
10.60 4.93% |
225.60 | - | - | 4.71 | 2.50 | 4.23 | -8.89 |
| OXB Oxford BioMedica PLC |
5.00 0.95% |
532.00 | - | 208.33 | 4.05 | 7.60 | 4.42 | 308.96 |
| AVCT Avacta Group PLC |
-1.00 1.60% |
61.50 | - | - | 2849.46 | 1929.84 | 2525.51 | -12.04 |
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits. Its products include Slimbiome, which offers a scientifically supported, non-pharmaceutical approach to reduce hunger and cravings; CholBiome, a food supplement for reducing cholesterol and blood pressure and supporting vascular health; and Sweetbiotix which are dietary fibres used as an alternative to sugar and existing sweeteners. The company also provides WellBiome a novel in vitro model of the human gut; OptiBiotics, a portfolio of prebiotics developed to target and enhance the growth of specific probiotics; and SlimBiome X3, a supplement that helps users cut calories without hunger and cravings. The company was formerly known as Ducat Ventures PLC and changed its name to OptiBiotix Health Plc in August 2014. OptiBiotix Health Plc was incorporated in 2006 and is headquartered in York, the United Kingdom.
| Name | Title | Year Born |
|---|---|---|
| Mr. Stephen Patrick O'Hara | Founder, CEO & Exec. Director | NA |
| Dr. Sofia Kolyda | Exec. Director of R&D and Exec. Director | 1973 |
| Mr. Rene Kamminga | CEO of Functional Fibres & Director | NA |
| Mr. Mark Kingsley Collingbourne | CFO & Sec. | 1966 |
| Paul Cannings | Head of Operations & Quality | NA |
| Kevin James Newman | Corp. Devel. Director | NA |
| Mr. Karl Burkitt | Marketing Director | NA |
| Mr. Stephen Patrick O'Hara | Founder, CEO & Executive Director | 1960 |
| Dr. Sofia Kolyda | Executive Director of Research & Development and Executive Director | 1973 |
| Mr. David Jonathan Blain ACA | CFO, Company Secretary & Director | 1961 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.